Drugmaker Merck & Co. is reporting lower first-quarter results and cutting its 2013 profit forecast by 15 cents a share. It also is announcing a huge share buyback, up to $15 billion worth of its stock.
Merck's first-quarter profit fell 8.3 percent and revenue by 9 percent, mainly because competition from generics slashed sales of its top seller, asthma and allergy drug Singulair.
The Whitehouse Station, N.J. company says net income was $1.59 billion, or 52 cents per share, down from $1.74 billion, or 56 cents per share, a year earlier.
Adjusted earnings were 85 cents per share, a nickel more than analysts expected.
Revenue totaled $10.67 billion, down from $11.73 billion. Analysts expected $11.11 billion.
Merck shares fell 99 cents to $46.01 in premarket trading.
Explore further: Merck's 2Q net falls on charges, but sales rise